Realising the promise of cell and gene therapies in Asia Pacific
Four imperatives for commercial delivery
The next generation of cell and gene therapies (CGTs) holds tremendous potential for therapeutic benefits. To realise this promise, stakeholders need to come together to optimise value chain and recalibrate commercial delivery.
The next generation of cell and gene therapies (CGTs) holds tremendous potential for therapeutic benefits. Based on Deloitte's vast experience in the commercial launch of CGT products, we discuss how stakeholders can come together to optimise value chain and recalibrate commercial delivery.
Overcoming biopharma's trust deficit
Why people mistrust the biopharma industry--and what to do about it
Consumers may appreciate pharma companies’ efforts to speed up the process of bringing COVID-19 vaccines to market. How might biopharma continue to innovate while building trust?
Breaking barriers to digitalization in biopharma
The pandemic's impact on R&D and commercial operating models
The COVID-19 pandemic has changed the way biopharma does business, from trials to manufacture to sales. Once things get back to normal, will it be business as usual or will the industry evolve and implement learnings from this period?
Maintaining value in pharmaceutical compliance
How can companies modernize programs through digital to deliver strategic value?
Rapid changes in the pharmaceutical industry call for a compliance upgrade. Adoption of digital technologies such as automation and machine learning can help compliance maintain its position as a strategic partner to the business.